Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell transplantation

Study type:

Study number:

84110121

Type of Stem Cell Treatment:

Allogeneic

Diseases:

All diseases

Short title:

Immune Checkpoint Inhibitors (ICI)

Primary objective:

Key inclusion criteria:

Country:

All EBMT member countries

Principal investigator:

Jan Brijs

EBMT Study coordinator:

William Boreland

Study coordinator email:

william.boreland@ebmt.org

EBMT Study Unit:

Paris Study Unit

Reason for processing personal data:

Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.

Categories of personal data collected:

DOB/YOB, gender

Medical data already reported to the EBMT Registry

Study Specific Questionnaire (MED-C)

Recipients who may access the data:

Paris Study Unit

Statistical Unit

3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Article 6 lawful basis for processing personal data:

Article 6.1 (a) - Consent (Collection)

Article 9 basis for processing special category data:

Article 9(2) (a) - Consent (Collection)

Rights available to individuals:

Access

Is a Data Protection Impact Assessment required?:

DPIA performed for EBMT Registry (WP & NIS Studies)

Retention Schedule (if possible):

at least 5 years after the final report or first publication of study results